221 related articles for article (PubMed ID: 19173002)
1. Altering mucus rheology to "solidify" human mucus at the nanoscale.
Lai SK; Wang YY; Cone R; Wirtz D; Hanes J
PLoS One; 2009; 4(1):e4294. PubMed ID: 19173002
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses.
Lai SK; Wang YY; Hida K; Cone R; Hanes J
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):598-603. PubMed ID: 20018745
[TBL] [Abstract][Full Text] [Related]
3. The microstructure and bulk rheology of human cervicovaginal mucus are remarkably resistant to changes in pH.
Wang YY; Lai SK; Ensign LM; Zhong W; Cone R; Hanes J
Biomacromolecules; 2013 Dec; 14(12):4429-35. PubMed ID: 24266646
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus.
Ensign LM; Lai SK; Wang YY; Yang M; Mert O; Hanes J; Cone R
Biomacromolecules; 2014 Dec; 15(12):4403-9. PubMed ID: 25347518
[TBL] [Abstract][Full Text] [Related]
5. Micro- and macrorheology of mucus.
Lai SK; Wang YY; Wirtz D; Hanes J
Adv Drug Deliv Rev; 2009 Feb; 61(2):86-100. PubMed ID: 19166889
[TBL] [Abstract][Full Text] [Related]
6. Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure.
Wang YY; Lai SK; So C; Schneider C; Cone R; Hanes J
PLoS One; 2011; 6(6):e21547. PubMed ID: 21738703
[TBL] [Abstract][Full Text] [Related]
7. The cervicovaginal mucus barrier to HIV-1 is diminished in bacterial vaginosis.
Hoang T; Toler E; DeLong K; Mafunda NA; Bloom SM; Zierden HC; Moench TR; Coleman JS; Hanes J; Kwon DS; Lai SK; Cone RA; Ensign LM
PLoS Pathog; 2020 Jan; 16(1):e1008236. PubMed ID: 31971984
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Trapping of HIV-1 by Human Cervicovaginal Mucus Is Associated with Lactobacillus crispatus-Dominant Microbiota.
Nunn KL; Wang YY; Harit D; Humphrys MS; Ma B; Cone R; Ravel J; Lai SK
mBio; 2015 Oct; 6(5):e01084-15. PubMed ID: 26443453
[TBL] [Abstract][Full Text] [Related]
9. A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease.
Hill DB; Vasquez PA; Mellnik J; McKinley SA; Vose A; Mu F; Henderson AG; Donaldson SH; Alexis NE; Boucher RC; Forest MG
PLoS One; 2014; 9(2):e87681. PubMed ID: 24558372
[TBL] [Abstract][Full Text] [Related]
10. Herpes simplex virus-binding IgG traps HSV in human cervicovaginal mucus across the menstrual cycle and diverse vaginal microbial composition.
Schroeder HA; Nunn KL; Schaefer A; Henry CE; Lam F; Pauly MH; Whaley KJ; Zeitlin L; Humphrys MS; Ravel J; Lai SK
Mucosal Immunol; 2018 Sep; 11(5):1477-1486. PubMed ID: 29988116
[TBL] [Abstract][Full Text] [Related]
11. Broadly neutralizing antibodies consistently trap HIV-1 in fresh cervicovaginal mucus from select individuals.
Schaefer A; Yang B; Schroeder HA; Harit D; Humphry MS; Ravel J; Lai SK
Acta Biomater; 2023 Oct; 169():387-397. PubMed ID: 37499728
[TBL] [Abstract][Full Text] [Related]
12. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
[TBL] [Abstract][Full Text] [Related]
13. Cervical mucus properties stratify risk for preterm birth.
Critchfield AS; Yao G; Jaishankar A; Friedlander RS; Lieleg O; Doyle PS; McKinley G; House M; Ribbeck K
PLoS One; 2013; 8(8):e69528. PubMed ID: 23936335
[TBL] [Abstract][Full Text] [Related]
14. Modeling of Virion Collisions in Cervicovaginal Mucus Reveals Limits on Agglutination as the Protective Mechanism of Secretory Immunoglobulin A.
Chen A; McKinley SA; Shi F; Wang S; Mucha PJ; Harit D; Forest MG; Lai SK
PLoS One; 2015; 10(7):e0131351. PubMed ID: 26132216
[TBL] [Abstract][Full Text] [Related]
15. Rheological properties of synthetic mucus for airway clearance.
Lafforgue O; Seyssiecq I; Poncet S; Favier J
J Biomed Mater Res A; 2018 Feb; 106(2):386-396. PubMed ID: 28960857
[TBL] [Abstract][Full Text] [Related]
16. Barrier properties of mucus.
Cone RA
Adv Drug Deliv Rev; 2009 Feb; 61(2):75-85. PubMed ID: 19135107
[TBL] [Abstract][Full Text] [Related]
17. Mucus from human bronchial epithelial cultures: rheology and adhesion across length scales.
Jory M; Donnarumma D; Blanc C; Bellouma K; Fort A; Vachier I; Casanellas L; Bourdin A; Massiera G
Interface Focus; 2022 Dec; 12(6):20220028. PubMed ID: 36330325
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical properties of mucus and their impact on transmucosal drug delivery.
Leal J; Smyth HDC; Ghosh D
Int J Pharm; 2017 Oct; 532(1):555-572. PubMed ID: 28917986
[TBL] [Abstract][Full Text] [Related]
19. [Gel-forming mucins structure governs mucus gels viscoelasticity].
Demouveaux B; Gouyer V; Magnien M; Plet S; Gottrand F; Narita T; Desseyn JL
Med Sci (Paris); 2018 Oct; 34(10):806-812. PubMed ID: 30451674
[TBL] [Abstract][Full Text] [Related]
20. Viscoelastic properties of suspended cells measured with shear flow deformation cytometry.
Gerum R; Mirzahossein E; Eroles M; Elsterer J; Mainka A; Bauer A; Sonntag S; Winterl A; Bartl J; Fischer L; Abuhattum S; Goswami R; Girardo S; Guck J; Schrüfer S; Ströhlein N; Nosratlo M; Herrmann H; Schultheis D; Rico F; Müller SJ; Gekle S; Fabry B
Elife; 2022 Sep; 11():. PubMed ID: 36053000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
